# Evaluate Safety and Efficacy of Apitox Add-on Therapy for Improving Disability and Quality of Life in MS Patients

> **NCT03710655** · PHASE3 · UNKNOWN · sponsor: **Apimeds, Inc.** · enrollment: 468 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Apitox - pure honeybee toxin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03710655
- **Lead sponsor:** Apimeds, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04
- **Primary completion:** 2019-08
- **Final completion:** 2019-11
- **Target enrollment:** 468 (ESTIMATED)
- **Last updated:** 2018-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03710655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03710655, "Evaluate Safety and Efficacy of Apitox Add-on Therapy for Improving Disability and Quality of Life in MS Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03710655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*